TREA

79213106 - OC

Follow

Information

  • Trademark
  • 79213106
  • Serial Number
    79213106
  • Registration Number
    5466730
  • Filing Date
    February 06, 2017
    7 years ago
  • Registration Date
    May 15, 2018
    6 years ago
  • Transaction Date
    December 18, 2024
    27 days ago
  • Status Date
    May 15, 2018
    6 years ago
  • Published for Opposition Date
    February 27, 2018
    6 years ago
  • Location Date
    December 18, 2024
    27 days ago
  • Status Code
    700
  • Current Location
    Historical data usage
    Employee Name
    SCHLEGELMILCH, JONATHON
  • Attorney Docket Number
    7955-0086
    Attorney Name
    Brian A. Tollefson
  • Owners
Information
Mark Drawing Code
3
Mark Identification
OC
Case File Statements
  • DM0000: The mark consists of two side-by-side, touching circles, in which the circle on the right has two breaks. The circle on the left is light blue on the left, blue in the middle, and green on the right. The broken circle on the right is three quarters green and the separated one quarter portion is light gray.
  • GS0051: Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all ] for use in human [ and veterinary ] medicine; Chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Prescription and non-prescription ] medicines, [ namely, pills, tablets, capsules, caplets, liquid drops, sachets, and ] pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; ] Biological preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; ] Biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Diagnostic preparations for medical purposes; ] Medicines for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; ] Biological reagents for medical use; Medicinal preparations based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; [ Medicinal preparations based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; Products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, natural killer cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ Gene therapy products, namely, genetically engineered tissues for transplant purposes; Medicaments, namely, cells and tissues that have been subjected to extensive manipulation, to help assist with the regeneration of ligament and tendon fibers; ] Preparations for personalized medicine made of [ autologous cells or proteins or ] nucleic acids derived from individual genomic sequences; [ Preparations made up of cells for medical or clinical use; ] Preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; Preparations made up of tissues, namely, biological tissue cultures for medical purposes; Vaccines; Recombinant proteins supplements; Therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ]
  • CC0000: The color(s) light blue, blue, green and light grey is/are claimed as a feature of the mark.
  • GS0421: Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; Research and development in the pharmaceutical and biotechnology fields; Research and development in the field of micro-organisms and cells; Research and development in the field of biochemistry; Scientific research and development in the field of biology; Research and development in the field of diagnostic preparations; Services of medical laboratories; Compiling medical information and data for research and development purposes in the medical and veterinary fields; Scientific and technological services, namely, scientific research and technical writing; Scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes in the field of biology
Case File Event Statements
  • 7/27/2017 - 7 years ago
    2 - LIMITATION FROM ORIGINAL APPLICATION ENTERED Type: LIMI
  • 7/27/2017 - 7 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 7/28/2017 - 7 years ago
    3 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 7/28/2017 - 7 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/31/2017 - 7 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 8/1/2017 - 7 years ago
    6 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 8/1/2017 - 7 years ago
    7 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 8/3/2017 - 7 years ago
    8 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 8/3/2017 - 7 years ago
    9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 10/20/2017 - 7 years ago
    12 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 8/18/2017 - 7 years ago
    10 - REFUSAL PROCESSED BY IB Type: RFNT
  • 10/20/2017 - 7 years ago
    11 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 2/7/2018 - 6 years ago
    22 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/3/2018 - 7 years ago
    13 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 1/18/2018 - 6 years ago
    14 - ASSIGNED TO LIE Type: ALIE
  • 1/22/2018 - 6 years ago
    15 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/22/2018 - 6 years ago
    16 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/25/2018 - 6 years ago
    17 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 1/25/2018 - 6 years ago
    20 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 1/25/2018 - 6 years ago
    18 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 1/25/2018 - 6 years ago
    19 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 1/25/2018 - 6 years ago
    21 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 2/27/2018 - 6 years ago
    25 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 5/15/2018 - 6 years ago
    26 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 8/15/2018 - 6 years ago
    27 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 8/24/2018 - 6 years ago
    29 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 9/15/2018 - 6 years ago
    30 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 10/24/2022 - 2 years ago
    33 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 2/22/2018 - 6 years ago
    23 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH
  • 2/27/2018 - 6 years ago
    24 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/24/2018 - 6 years ago
    28 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 4/9/2021 - 3 years ago
    31 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 10/24/2022 - 2 years ago
    34 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 10/24/2022 - 2 years ago
    35 - TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Type: EWAF
  • 10/24/2022 - 2 years ago
    38 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 10/24/2022 - 2 years ago
    36 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR
  • 10/24/2022 - 2 years ago
    37 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 10/24/2022 - 2 years ago
    32 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 5/15/2023 - a year ago
    39 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3
  • 12/16/2024 - 29 days ago
    41 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE
  • 12/18/2024 - 27 days ago
    42 - POST REGISTRATION ACTION MAILED - SEC. 71 & 15 Type: PR75
  • 5/14/2024 - 8 months ago
    40 - TEAS SECTION 71 & 15 RECEIVED Type: ES75